國藥控股(01099.HK):上半年歸母淨利41.04億元 同比增長11.12%
格隆匯8月28日丨國藥控股(01099.HK)發佈公吿,截至2023年6月30日止六個月,報吿期內,集團實現業務收入人民幣3009.50億元,同比增長15.10%。本期溢利達到人民幣68.93億元,同比增長10.67%,歸屬於母公司持有者溢利達到人民幣41.04億元,同比增長11.12%,本期溢利和歸屬於母公司持有者溢利均實現雙位數增長,指標增速持續超過行業平均水平。
同時,按照本集團“十四五”期間的業務發展規劃,三個主營業務板塊的營業收入在報吿期內均實現雙位數增長,市場份額穩步提升。截至報吿期末,醫藥分銷業務收入為人民幣2254.33億元,同比增長14.71%,增速較往年明顯提升。醫藥分銷板塊收入佔集團整體收入的比重為72.37%,較上年同期下降0.32個百分點,降幅則顯着放緩。醫療器械業務收入達到人民幣629.54億元,同比增長17.27%,收入佔比為20.21%,較上年同期增加0.35個百分點,醫藥零售業務收入為人民幣176.97億元,同比增長15.86%,收入佔比為5.68%,較上年同期增加0.03個百分點。
集團在推動運營效率不斷改善的同時,側重盈利能力和業務質量的優化。報吿期內,集團的銷管費用率、財務費用率同比均有所下降,規模效應穩步顯現。截至報吿期末,集團的銷管費用率同比下降0.25個百分點,為4.12%;其中銷售費用率為2.80%,同比下降0.17個百分點,管理費用率為1.32%,同比下降0.08個百分點。上半年財務費用率為0.47%,較上年同期下降0.14個百分點。應收週轉天數同比優化9天,營運週期同比優化7天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.